Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 18/20 | 0.48 |
| ▸ | KDM4A | O75164 | 13/20 | 0.48 |
| ▸ | KDM5A | P29375 | 6/20 | 0.48 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.48 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.48 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14944835 | 0.81 | ALDH1A1 (0.47) | KDM4A | |
| SCHEMBL1156661 | 0.80 | MMP2 (0.36) | KDM4A | |
| SCHEMBL14566299 | 0.76 | ALDH1A1 (0.48) | KDM4CKDM4AKDM5APHF8KDM2A | |
| SCHEMBL7607485 | 0.75 | FOLH1 (0.50) | — | |
| SCHEMBL440142 | 0.74 | PHF8 (0.44) | KDM4CKDM4AKDM5APHF8KDM2A | |
| SCHEMBL18770949 | 0.72 | — | — | |
| SCHEMBL8746938 | 0.72 | KDM4A (0.47) | KDM4CKDM4AKDM5APHF8KDM2A | |
| SCHEMBL5136363 | 0.72 | — | — | |
| SCHEMBL7707701 | 0.72 | KDM4A (0.47) | KDM4CKDM4AKDM5APHF8KDM2A | |
| SCHEMBL11710345 | 0.72 | LMNA (0.42) | KDM4CKDM4AKDM5APHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595613-B1 | COMPOUNDS FOR USE IN A METHOD OF PREVENTING OR TREATING VIRAL INFECTION | US HEALTH (US) | 2019-01-09 | — | — | EP | disclosed |
| US-8871789-B2 | Method of preventing or treating viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2012012627-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | KDM1B, KDM1A, KDM2A | KDM4C 20/4885KDM4A 9/4885KDM5A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.